Published in Am J Respir Crit Care Med on October 01, 1999
Maintenance of airway epithelium in acutely rejected orthotopic vascularized mouse lung transplants. Am J Respir Cell Mol Biol (2007) 1.33
Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov (2010) 1.24
Smad3 deficiency ameliorates experimental obliterative bronchiolitis in a heterotopic tracheal transplantation model. Am J Pathol (2004) 1.14
The heterotopic tracheal allograft as an animal model of obliterative bronchiolitis. Respir Res (2001) 1.10
Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation. Semin Respir Crit Care Med (2013) 0.98
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst (1999) 2.81
Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res (2001) 2.79
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res (2000) 2.43
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 2.37
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res (2000) 1.88
Identification by molecular cloning of an autoantigen associated with Addison's disease as steroid 17 alpha-hydroxylase. Lancet (1992) 1.73
Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res (2001) 1.53
Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res (2000) 1.39
The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res (1999) 1.39
Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines. Arch Virol (1994) 1.34
Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev (2001) 1.33
Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer (2002) 1.32
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem (2000) 1.21
Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem (1997) 1.13
Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J (1997) 1.12
Successful amplification of DNA specific for Finnish Borrelia burgdorferi isolates in erythema chronicum migrans but not in circumscribed scleroderma lesions. J Invest Dermatol (1994) 1.04
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res (2001) 1.03
Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta. Proc Natl Acad Sci U S A (1999) 1.02
Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease. J Clin Endocrinol Metab (1994) 1.01
Cytomegalovirus infection and accelerated cardiac allograft vasculopathy in human cardiac allografts. J Heart Lung Transplant (1993) 0.97
Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc Drugs Ther (1999) 0.96
Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J (1995) 0.93
Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem (1994) 0.92
Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis (1999) 0.91
Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther (1999) 0.88
4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem (1996) 0.88
Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. J Pharm Belg (1997) 0.86
Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. Circulation (1999) 0.85
Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts. Am J Transplant (2014) 0.85
Protocol core needle biopsy and histological chronic allograft damage index as surrogate endpoint for Long-Term graft survival. Transplant Proc (2004) 0.85
[(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase. J Med Chem (1995) 0.85
Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol (2004) 0.85
Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. Br J Haematol (1998) 0.83
Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis. Transplant Proc (2006) 0.83
Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. Gene Ther (2007) 0.83
Cytomegalovirus infection accelerates cardiac allograft vasculopathy: correlation between angiographic and endomyocardial biopsy findings in heart transplant patients. Transpl Int (1993) 0.82
The effect of platelet-derived growth factor ligands in rat cardiac allograft vasculopathy and fibrosis. Transplant Proc (2006) 0.82
How cyclosporine modifies histological and molecular events in the vascular wall during chronic rejection of rat cardiac allografts. Am J Pathol (1995) 0.82
Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat. Circulation (1994) 0.82
Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts. Am J Respir Crit Care Med (2001) 0.82
Blockade of complement inhibits obliterative bronchiolitis in rat tracheal allografts. Am J Respir Crit Care Med (2000) 0.81
Effect of ganciclovir prophylaxis on cytomegalovirus-enhanced allograft arteriosclerosis. Transpl Int (1994) 0.81
Expression and localization of platelet-derived growth factor ligand and receptor protein during acute and chronic rejection of rat cardiac allografts. Circulation (1997) 0.80
Role of nitric oxide in experimental obliterative bronchiolitis (chronic rejection) in the rat. J Clin Invest (1997) 0.80
Donor simvastatin treatment prevents ischemia-reperfusion and acute kidney injury by preserving microvascular barrier function. Am J Transplant (2013) 0.80
Mechanisms of chronic rejection. Transplant Proc (1999) 0.79
Cytomegalovirus infection enhances experimental obliterative bronchiolitis in rat tracheal allografts. Am J Respir Crit Care Med (1997) 0.79
Mast cells in acute and chronic rejection of rat cardiac allografts--a major source of basic fibroblast growth factor. Transplantation (2001) 0.79
Adhesion molecule P-selectin and vascular cell adhesion molecule-1 in enhanced heart allograft arteriosclerosis in the rat. Circulation (1997) 0.79
A dose-dependent inhibitory effect of cyclosporine A on obliterative bronchiolitis of rat tracheal allografts. Am J Respir Crit Care Med (1997) 0.78
Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett (2000) 0.78
Cytomegalovirus infection-enhanced chronic kidney allograft rejection is linked with intercellular adhesion molecule-1 expression. Kidney Int (1996) 0.78
Enhanced intimal proliferation upon injury to pre-existing neointima and resistance of neointimal cells to cell death. Cardiovasc Pathol (2000) 0.78
Retracted A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo. Int J Cancer (1998) 0.77
Differential effects of pharmacological HIF preconditioning of donors versus recipients in rat cardiac allografts. Am J Transplant (2013) 0.77
Immunobiology and pathology of chronic rejection. Transplant Proc (1997) 0.77
Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease. Br J Cancer (2002) 0.77
Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Cancer Chemother Pharmacol (1999) 0.77
Inhibition of tumor necrosis factor-alpha does not prevent cardiac allograft arteriosclerosis in the rat. Transplant Proc (2001) 0.77
Expression of estrogen receptor sub-types alpha and beta in acute and chronic cardiac allograft vasculopathy. J Heart Lung Transplant (2001) 0.77
Inhibition of obliterative bronchiolitis by platelet-derived growth factor receptor protein-tyrosine kinase inhibitor. Transplant Proc (1999) 0.76
Steroid 21-hydroxylase gene polymorphism in Addison's disease patients. Tissue Antigens (1995) 0.76
Transcomplementation of simian immunodeficiency virus Rev with human T-cell leukemia virus type I Rex. J Virol (1993) 0.75
Triple drug immunosuppression significantly reduces aortic allograft arteriosclerosis in the rat. Arterioscler Thromb Vasc Biol (1996) 0.75
High endothelial cells synthesize and degrade sLex. Putative implications for L-selectin-dependent recognition. FEBS Lett (1999) 0.75
Role of growth factors in graft vessel disease. Transplant Proc (1997) 0.75
Structure of carotid artery in baboon and rat and differences in their response to endothelial denudation angioplasty. Ann Med (2001) 0.75
Chronic allograft rejection. Transplant Proc (1996) 0.75
Author errata. Int J Cancer (1999) 0.75
Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. Transplant Proc (1999) 0.75
Obliterative bronchiolitis: prevention. Transplant Proc (2001) 0.75
Chronic rejection: potential new sites of therapy. Transplant Proc (1996) 0.75
Endothelin-1 is biologically active in experimental rat obliterative bronchiolitis. Transplant Proc (2001) 0.75
Vascular cell adhesion molecule-1 (VCAM-1) is induced during cytomegalovirus infection in vascular structures of heart allografts. Transpl Int (1994) 0.75
CD28-B7-2 but not CD28-B7-1 interaction is required for T cell costimulation in experimental obliterative bronchiolitis in the rat. Transplant Proc (2001) 0.75
Effect of graft preservation and acute rejection on hypoxia-inducible factor-1 in rat cardiac allografts. Transplant Proc (2006) 0.75
Protein tyrosine kinase and protein kinase C inhibition by fungal anthraquinones related to emodin. J Antibiot (Tokyo) (1995) 0.75
PDGF receptor inhibition prevents cardiac allograft arteriosclerosis in cholesterol-fed rabbits. Transplant Proc (2001) 0.75
Rational drug design: making drugs that make a difference. Transplant Proc (2002) 0.75
Blockade of growth factor synthesis and growth factor action: two possible sites of interference in allograft vessel disease and coronary bypass or balloon injury. Metabolism (1996) 0.75
Retractions. Proc Natl Acad Sci U S A (1998) 0.75
[Legislation for the protection of employees]. Sairaanhoitaja (1967) 0.75
Emerging therapeutic strategies for the prevention and treatment of chronic allograft rejection. Transplant Proc (2000) 0.75
Molecular biology of transplant arteriosclerosis and sites of therapeutic intervention. Transplant Proc (2001) 0.75
Evolution of heart rate variability in cardiac transplant recipients: a clinical study. J Intern Med (1996) 0.75